Dexamethasone - Retinal Vein Occlusion

You are here : Home > Formulary Search > Dexamethasone - Retinal Vein Occlusion

I agree that in using this database I understand that this platform only provides guidance on local prescribing policy and that all prescribing decisions are ultimately the responsibility of the clinician.

Status 1

Red

Formulations :

Intravitreal implant

Formulary Status :

Primary Care

ASPH

RSFT

SASH

SABP

Associated Icons :

Guidelines BNF SPC

ICB

NICE

Restrictions / Comments :

Documentation

Evidence Review

Achieving and demonstrating compliance with NICE TA and HST guidance - NICE January 2016

Webpage

NICE TA229 - Dexamethasone intravitreal implant for the treatment of macular oedema secondary to retinal vein occlusion - July 2011

PAD Profile

ChemicalSubstance :

Dexamethasone

Indication :

Retinal Vein Occlusion

Group Name :

Keywords :

RVO, CRVO, BRVO, macular oedema, branch retinal vein occlusion, central retinal vein occlusion

Brand Names Include :

Ozurdex

Important Information :

Ophthalmology specialists only

Latest Additions Date From :

Latest Additions Date To :

Guidelines :

Retinal Vein Occlusion

Supporting Documents :

Other Indications

Below are listed other indications that Dexamethasone is used to treat.

Other Drugs

Below are listed other drugs that are used to treat Retinal Vein Occlusion.

Committee Recommendations (1)

05 Oct 16 - Surrey & North West Sussex Area Prescribing Committee (formerly Prescribing Clinical Network)

The PCN recommends intravitreal dexamethasone (Ozurdex) as a treatment option for the first line treatment of visual impairment caused by macular oedema secondary to branch or central retinal vein occlusion in line with NICE TA 229 (July 2011) and the NICE FAQ document relating to local formularies (link to document below). Intravitreal dexamethasone will be considered RED on the traffic light system